TABLE 1.
Efficacy of 15 drugs and antiviral compounds against four EV-D68 strains
| Drug or antiviral compound | Mean EC50 ± SD (μM) |
|||
|---|---|---|---|---|
| USA-MO/18947 | USA-MO/18949 | USA-IL/18956 | Fermon | |
| EV or RV capsid inhibitors | ||||
| Pleconarila,b | 4.44 ± 0.55 | 6.09 ± 0.26 | 6.11 ± 1.05 | 0.38 ± 0.01 |
| Pocapavira | >10 | >10 | >10 | >10 |
| Vapendavira | >10 | >10 | >10 | >10 |
| EV or RV protease inhibitors | ||||
| Rupintrivira | 0.0046 ± 0.0016 | 0.0015 ± 0.003 | 0.0037 ± 0.007 | 0.002 ± 0.0005 |
| V-7404c | 0.026 ± 0.004 | 0.027 ± 0.008 | 0.024 ± 0.007 | 0.0035 ± 0.0006 |
| Influenza virus inhibitors | ||||
| Amantidined | >10 | >10 | >10 | >10 |
| Arbidola,e | >10 | >10 | >10 | >10 |
| DAS181a | 0.0036 ± 0.0015 | 0.0026 ± 0.0012 | 0.004 ± 0.0016 | 0.0012 ± 0.0009 |
| Favipiravira | >10 | >10 | >10 | >10 |
| Oseltamivird | >10 | >10 | >10 | >10 |
| Approved for other indications | ||||
| Fluoxetined | 0.53 ± 0.15 | 0.64 ± 0.17 | 1.05 ± 0.2 | 0.34 ± 0.04 |
| Formoterol fumarated | >10 | >10 | >10 | >10 |
| Itraconazoled | >10 | >10 | >10 | >10 |
| Mefloquined | >10 | >10 | >10 | >10 |
| Nitazoxanided | >10 | >10 | >10 | >10 |
a
Completed a phase II clinical trial but not yet FDA approved.
b
In HeLa H1 cells, the EC50s of pleconaril for the four strains were 0.131 ± 0.024, 0.358 ± 0.036, 0.321 ± 0.094, 0.36 ± 0.021 μM, respectively. For other compounds, the values were not significantly different in the two cell lines (data not shown).
c
Completed a phase I clinical safety trial.
d
FDA approved for an indication other than EV or RV infection.
e
Licensed for human use in Russia and China.